Home Archives July 2008 State wins case against Merck

State wins case against Merck

| Print |  Email
Tuesday, July 01, 2008

STATEWIDE Oregon’s lead role in a record-breaking settlement with Merck & Co. over deceptive marketing for the anti-inflammatory drug Vioxx represents the latest skirmish in an ongoing campaign against Big Pharma that has earned the state more than $8.5 million.

After leading a three-year, 30-state investigation into deceptive advertisements downplaying the health risks associated with Vioxx, Oregon received $2.8 million of the record $58 million paid out by Merck. The judgment banned Merck from manipulating data when marketing to physicians, “ghost writing” articles for medical journals and failing to disclose conflicts of interest among doctors who study and promote drugs on behalf of the company.

The Vioxx settlement reflects growing concerns over how drug companies hook consumers on prescription drugs. Drug giants have poured billions into “demand creation” since the federal government loosened rules prohibiting “direct-to-consumer” advertising in 1997. In 2007 Oregon was the lead state in an $8 million settlement against Bayer for minimizing the dangers of Baycol, and also was in on a $19.5 million settlement against Purdue Pharma regarding OxyContin.

State officials cannot comment about current cases involving major pharmaceutical firms, but Oregon’s campaign against Big Pharma is clearly far from finished. Leading the way has been assistant attorney general David Hart, who worked in health care prior to pursuing consumer law and is married to a pharmacist. Hart has served as lead investigator and negotiator on all of Oregon’s major drug company cases. “The money we’ve gotten in these settlements gets put to good use, but these cases aren’t about the money,” he says, “they’re about the rules we create and the light that we shed on these practices so that we can change them.”

Ken Johnson, vice president of the Pharmaceutical Research and Manufacturers of America, said in a prepared statement that drug companies “are committed to providing accurate, educational information to patients and health professionals about their medicines.”


BEN JACKLET


To comment, email This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

 

More Articles

A Good Leap Forward

September 2014
Wednesday, August 27, 2014
BY AMY MILSHTEIN

Agriculture businesses ramp up to meet international demand as workforce and succession challenges loom.


Read more...

100 Best Nonprofits announced

News
Thursday, October 02, 2014

100NP14logo4WebOregon Business magazine has named the sixth annual 100 Best Nonprofits to Work for in Oregon.


Read more...

Downtime

October 2014
Thursday, September 25, 2014
BY JESSICA RIDGWAY

I'm not very interesting,” says a modest Ray Di Carlo, CEO and executive producer of Bent Image Labs, an animation and visual effects studio.


Read more...

The Rail Baron

October 2014
Thursday, September 25, 2014
BY LINDA BAKER

Oil is gushing out of the U.S. and Canada, and much of it is coming from places that don’t have pipeline infrastructure. So it’s being shipped by rail.


Read more...

Fork & Bottle

October 2014
Thursday, September 25, 2014

National media can’t get enough of Oregon’s pinot noir, artisan-food purveyors and lively, independent film scene.


Read more...

College Hacker

September 2014
Wednesday, August 27, 2014
BY KLINT FINLEY

Treehouse CEO Ryan Carson builds a 21st-century trade school.


Read more...

Podcast: Testing for Emotional Intelligence with John Hersey

Contributed Blogs
Friday, September 19, 2014
ivbU3sIXBY TOM COX | OB BLOGGER

How can you tell if you, a peer, a subordinate or a job candidate has the emotional intelligence needed to do well?


Read more...
Oregon Business magazinetitle-sponsored-links-02
SPONSORED LINKS